PROF ROBERT HEYDERMAN
MALAWI-LIVERPOOL-WELLCOME TRUST RESEARCH PROGRAMME
Rob Heyderman is Professor of Tropical Medicine and Director of the Malawi-Liverpool-Wellcome Trust Clinical Research Programme.
He trained in London and Zimbabwe. His current research interests comprise the endothelial biology and coagulopathy immunology of severe infection; the development of naturally acquired immunity to Neisseria meningitidis and Streptococcus pneumoniae; regulation of the host inflammatory response; and the clinical diagnosis and management of meningitis and septicaemia.
Current initiatives include new approaches to mucosal vaccination to prevent pneumonia and meningitis both in the UK and in the tropics; management of meningitis and severe sepsis in resource-poor settings; and microbial genetic diversity in the contact of HIV infection.
Prof Heyderman will be chairing the opening session of day one - Counting the Cost of Meningitis and Septicaemia.
DR MARY RAMSAY
HEALTH PROTECTION AGENCY, CENTRE FOR INFECTIONS
Dr Mary Ramsay is a Consultant Epidemiologist in the Immunisation Department at the Health Protection Agency, Centre for Infections in Colindale, London. Dr Ramsay joined the Agency in 1994 after training in Public Health Medicine and holding an academic post at St Mary’s Hospital Medical School, London. She is responsible for surveillance of polio, measles, Hib and meningococcal disease, hepatitis B and C in England and Wales. As temporary advisor to the WHO European Office she wrote the strategy for measles elimination in Europe, and provides epidemiological input into ELSM, a European research network for the laboratory surveillance of measles. Her research interests involve establishing the potential role for new vaccines.
Dr Ramsay will be chairing The science and policy of prevention session on day one.
PROF ADAM FINN
UNIVERSITY OF BRISTOL
Professor Adam Finn is Head of the Academic Unit of Child Health at Bristol Medical School, Dept of Clinical Science South Bristol and an honorary consultant in paediatric infectious diseases and immunology at Bristol Royal Hospital for Children. He is director of the South West Medicines for Children Research Network and heads the Bristol Children's Vaccine Centre. He trained in Infectious Diseases at the Children's Hospital of Philadelphia and in Immunology at the Institute of Child Health in London where he obtained his PhD.
He worked in Sheffield between 1992 and 2001 where he was involved in several trials of meningococcal group C and other vaccines. His current main research interest is the mucosal immune response to respiratory bacteria including pneumococcus and meningococcus.
Prof Finn will be chairing the Issues in prevention of pneumococcal disease session on day one, and will also be taking part in the Wyeth Vaccines satellite debate.
PROF BRIAN GREENWOOD
LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE
Brian Greenwood qualified in medicine at the University of Cambridge, UK in 1962. Following house-officer appointments in London, he spent three years in Western Nigeria as a medical registrar and research fellow at University College Hospital, Ibadan. After receiving training in clinical immunology in the UK, he returned to Nigeria in 1970, this time to help in establishing a new medical school at Ahmadu Bello University, Zaria where he developed his research interests in malaria and meningococcal disease whilst continuing to teach and practice clinical medicine.
In 1980, he moved to the UK Medical Research Council Laboratories in The Gambia which he directed for the next 15 years. In The Gambia, he helped to establish a multi-disciplinary research programme which focused on some of the most important infectious diseases prevalent in The Gambia and neighbouring countries such as malaria, pneumonia, measles, meningitis, hepatitis and HIV2. Work undertaken during this period included demonstration of the efficacy of insecticide treated bednets in preventing death from malaria in African children and demonstration of the impact of Haemophilus influenzae type b and pneumococcal conjugate vaccines when deployed in sub-Saharan Africa.
In 1996, he was appointed to the staff of the London School of Hygiene and Tropical Medicine where he is now Manson Professor of Clinical Tropical Medicine. From 2001 -2009 he directed the Gates Malaria Partnership which supported a programme of research and capacity development in many countries in Africa directed at improving treatment and prevention of malaria. In 2008, he became director of a new capacity development initiative supported by the Wellcome Trust and the Bill and Melinda Gates Foundation, the Malaria Capacity Development Consortium (MCDC), which operates a post-graduate malaria training programme in five countries in sub-Saharan Africa, and he also directs a new consortium (MenAfriCar) established with support from the Wellcome Trust and the Bill and Melinda Gates Foundation to study meningococcal carriage in Africa.
Prof Greenwood will be chairing the Future prevention of meningitis in developing countries session on day one.
DR CHRIS WORTH
UK MEDICAL DIRECTOR, NOVARTIS VACCINES
Dr Chris Worth is UK Medical Director for Novartis Vaccines and is based at the Frimley (UK) office. He graduated in medicine from Nottingham University Medical School.
After working for some years in general practice in the Midlands, Chris became a successful Director of Public Health for a number of Health Authorities within the UK National Health Service (NHS) during the 1990s. He actively contributed to UK and local public health policy and wrote a number of scientific publications.
Chris joined Janssen-Cilag (part of Johnson & Johnson) in 2000 as Head of Medical Affairs before moving to GSK as their UK Head of Vaccines in 2005. He has been with Novartis Vaccines since May 2007. Chris' current role is to head medical affairs activities in the UK/Ireland across the whole portfolio with special reference to meningococcal diseases.
Dr Worth will be chairing the Novartis Vaccines Satellite Session on Day Two
PROF NIGEL KLEIN
GREAT ORMOND STREET CHILDREN'S HOSPITAL AND THE INSTITUTE OF CHILD HEALTH
Professor Nigel Klein is Professor and Consultant in Paediatric Infectious Diseases and Immunology at Great Ormond Street Children’s Hospital, London, and the Institute of Child Health, University College London. He trained at UCL, obtaining degrees in Anatomy and in Medicine. He is currently Head of the Infectious Diseases and Microbiology Unit at ICH and Deputy Head of the Research Department of Infection at UCL. He has been working in the fields of Meningitis and Sepsis for many years, in both a clinical and academic capacity.
Prof Klein will be chairing the Current issues in treatment session on day two.
PROF MICHAEL LEVIN
IMPERIAL COLLEGE LONDON
Michael Levin is Professor of Paediatrics and International Child Health at Imperial College London. He trained in medicine in South Africa and in paediatrics in the UK before specialising in infectious diseases. He was Consultant in Infectious Diseases at Great Ormond Street hospital before being appointed as Professor of Paediatrics at Imperial College London in 1990. His research has focused on life threatening infections of childhood: (a) meningococcal disease and (b) childhood tuberculosis. (c) severe malaria.
Professor Levin currently heads an international EU funded consortium studying novel diagnostic methods for tuberculosis in Africa and also leads an EU funded consortium studying the genetic basis of meningococcal disease.
Prof Levin will be chairing the Management of sepsis and meningitis session on day two.
PROF DAVID LALLOO
LIVERPOOL SCHOOL OF TROPICAL MEDICINE
David Lalloo is Professor of Tropical Medicine at the Liverpool School of Tropical Medicine, Director of the Wellcome Trust Liverpool Tropical Centre and an Honorary Consultant at the Royal Liverpool University Hospital. He trained in Infectious Diseases and Tropical Medicine in London, Papua New Guinea and Oxford, before moving to Liverpool in 1999. His major research interests are in clinical trials in the tropics, particularly in HIV related infections, meningitis and malaria and he currently works in a number of countries including Uganda, Malawi, Sri Lanka and Vietnam.
Prof Lalloo will be chairing the Prevention of Meningococcal Disease session on day two, when he will also hand over the award for the best poster, kindly donated by Wyeth Vaccines.
PROF ANDREW POLLARD
UNIVERSITY OF OXFORD, UK
Andrew J Pollard, FRCPCH PhD, is Professor of Paediatric Infection and Immunity at the University of Oxford, Director of the Oxford Vaccine Group in the University Department of Paediatrics, Fellow of St Cross College and Honorary Consultant Paediatrician at the Children’s Hospital, Oxford, UK. He chairs the UK’s NICE meningitis guidelines development committee. He obtained his medical degree at St Bartholomew’s Hospital Medical School, University of London in 1989 and trained in Paediatrics at Birmingham Children’s Hospital, UK, specialising in Paediatric Infectious Diseases at St Mary’s Hospital, London, UK and at British Columbia Children’s Hospital, Vancouver, Canada. He obtained his PhD at St Mary’s Hospital, London, UK in 1999 studying immunity to Neisseria meningitidis
in children and proceeded to work on anti-bacterial innate immune responses in children in Canada before returning to his current position at the University of Oxford, UK in 2001.
Current research activities include clinical trials of new and improved vaccines for children, invasive bacterial diseases in children in Nepal, studies of cellular and humoral immune responses to glycoconjugate vaccines, research on the genetic control of the human immune response and investigations on meningococcal host-pathogen interactions and development of a serogroup B meningococcal vaccine. His publications include over 200 manuscripts and books on various topics in paediatrics, and infectious diseases.
Prof Pollard will be presenting NICE guideline on meningococcal disease and bacterial meningitis and bacterial meningitis in children, read the abstract here.
He will be joint chair for the session Future prevention of MenB and initiate the round-table discussion.
He will also be taking part in the Novartis Vaccines Satellite Session and the Wyeth Vaccines Satellite Debate.
PROF RAY BORROW
DIRECTOR VACCINE DEVELOPMENT UNIT, HPA MANCHESTER, UK
Prof Ray Borrow is Head of the Vaccine Evaluation Unit at the Health Protection Agency North West, Manchester, UK, where he is responsible for the evaluation of serological responses to various bacterial and viral vaccines with a special interest in meningococcal and pneumococcal vaccines. He gained his PhD in 1994 and his MRCPath in 2003. His scientific findings resulted in over 150 peer reviewed published papers. He serves as a member of the DoH Joint Committee of Vaccination and Immunisation (JCVI) and frequently advises WHO and companies on both meningococcal and pneumococcal vaccines. He sits on the medical-scientific advisory panel for the Meningitis Trust, Meningitis Research Foundation and Meningitis UK.
Prof Borrow will be jointly chairing the Future prevention of MenB session on day two.
PROF DAVID GOLDBLATT
INSTITUTE OF CHILD HEALTH, UNIVERSITY COLLEGE LONDON, UK
Professor David Goldblatt is Professor of Vaccinology and Immunology and Head of the Immunobiology Unit at the Institute of Child Health, University College London as well as a Consultant Paediatric Immunologist at the Great Ormond Street Hospital for Children NHS Trust. He is the Director of Clinical Research and Development for the joint Institution where he is also Director of National Institute for Health Research (NIHR) Specialist Biomedical Research Centre. He was recently appointed as Director of the UCL Partners Acadmeic Health Science Child Health Theme. He obtained his medical degree from the University of Cape Town, South Africa, his Paediatric qualifications from the Royal College of Physicians (London) and a PhD in Immunology from the University of London, United Kingdom.
He has a long-standing interest in the immune response to vaccines and infectious diseases in childhood and has an active research programme studying bacterial conjugate vaccines, the kinetics of immunological memory and immunity and infections in early life. He is involved in clinical trials and basic science research projects in the United Kingdom, Africa and SE Asia and collaborates with colleagues in Europe and the USA. He is a regular advisor to the World Health Organisation (WHO) on bacterial conjugate vaccines and is Director of the WHO Reference Laboratory for Pneumococcal Serology based at the UCL Institute of Child Health in London. He served as a member of the United Kingdom Department of Health Joint Committee on Vaccines and Immunisation for 10 years (1997-2007) and is currently co-chairman of the Wellcome Trust Immunology and Infectious Disease Funding Committee panel.
Prof Goldblatt will be chairing the debate during the Wyeth satellite session on day one